TNBC is a description of the immunophenotype of BC that is negative for ER, PR, and HER‐2, whereas basal‐like BC describes the molecular phenotype, with approximately 50% of TNBC falling within this subtype (Figure 1).14 This evidence concerns the gene PGR and breast cancer.